Show results for
Refine by
Locations
- Europe
- Albania
- Andorra
- Austria
- Belarus
- Belgium
- Bosnia & Herzegovina
- Bulgaria
- Croatia
- Cyprus
- Czech Republic
- Denmark
- Estonia
- Faroe Islands
- Finland
- France
- Germany
- Greece
- Hungary
- Iceland
- Ireland
- Italy
- Kosovo
- Latvia
- Liechtenstein
- Lithuania
- Luxembourg
- Macedonia
- Malta
- Moldova
- Monaco
- Montenegro
- Netherlands
- Northern Ireland
- Norway
- Poland
- Portugal
- Romania
- San Marino
- Serbia
- Slovakia
- Slovenia
- Spain
- Sweden
- Switzerland
- Turkey
- Ukraine
- United Kingdom
- Vatican City
Phase 1 Clinical Equipment Supplied In Europe
82 equipment items found
Manufactured by:Adaptimmune LLC based inPhiladelphia, PENNSYLVANIA (USA)
Our ADP-A2AFP SPEAR T-cell product targets alpha-fetoprotein (AFP) is being investigated in an ongoing Phase 1 clinical trial for the treatment of patients with hepatocellular carcinoma (liver ...
Manufactured by:TC BioPharm based inHolytown, UNITED KINGDOM
TCB002 is an unmodified allogeneic gamma delta T cell product, being initially used for the treatment of Acute Myeloid Leukaemia (AML). This product is currently undergoing a phase 1 clinical trial as part of a dose escalation and safety study, in partnership with ÚKHT, Institute of Hematology and Blood Transfusion, Prague. AML is a cancer ...
Manufactured by:Treos Bio Limited based inLondon, UNITED KINGDOM
In silico trials predicted that these peptides induce exceptionally broad T cell responses against at least 3 tumor-specific antigens in high proportion of patients, without need of biopsy. Phase 1 clinical study is completed to confirm the predictions in patients with metastatic colorectal cancer (NCT03391232, Hubbard et al ASCO 2020). ...
Manufactured by:Novavax based inGaithersburg, MARYLAND (USA)
In 5 separate studies, carried out in collaboration with the National Institute of Allergy and Infectious Diseases, active immunization with the Ebola GP vaccine was shown to be highly immunogenic and efficacious in preventing lethal disease in non-human primates challenged with EBOV. Our 2015 Phase 1 clinical trial demonstrated that our Ebola GP ...
Manufactured by:Kiadis Pharma NV based inAmsterdam, NETHERLANDS
We believe this mechanism-of-action means Amlitelimab could be applicable to a range of autoimmune and inflammatory diseases. In our Phase 1 clinical trial in healthy volunteers, Amlitelimab was able to block T cell-driven skin inflammation while being well tolerated. We believe the immune-modulating mechanism of Amlitelimab has broad potential ...
Manufactured by:Gesynta Pharma AB based inStockholm, SWEDEN
Gesynta Pharma’s drug candidate GS-073 is expected to enter clinical phase I in 2022. It is currently in the final stages of preclinical development. This project will be addressing an indication with high unmet need, which is separate from systemic ...
Manufactured by:BCN Peptides S.A. based inSant Quintí de Mediona, SPAIN
Where can BCN Peptides assist your peptide project? BCN Peptides is an industrial manufacturer with the capacity to produce from milligram to multi-kg batches of pharmaceutical peptides. We are experts in the synthesis of long and complex New Chemical Entities. BCN Peptides ensures the highest qualities and shortest times thanks to our experience in the manufacturing of peptides for all clinical ...
by:STALICLA based inGeneve, SWITZERLAND
STALICLA is advancing a robust pipeline of both proprietary and partnered therapeutic ...
Manufactured by:Addex Therapeutics based inGeneva, SWITZERLAND
Our partner, Indivior, has licensed worldwide rights to our GABAB PAM program and is responsible for all development, manufacture and commercialization of any selected GABAB PAM drug candidates. Under the agreement, we are responsible for executing a research program funded by Indivior to discover novel drug candidates. Indivior has the right to select GABAB PAM drug candidates from our research ...
Manufactured by:Poietis based inPessac, FRANCE
NGB-C is a clinical-grade, GMP-compliant Bioprinter designed to meet the needs of Advanced Therapy Medicinal Products (ATMP) production and the requirements of Poietis’ ...
by:Genmab A/S based inCopenhagen V, DENMARK
DuoBody-CD40x4-1BB (GEN1042) is a proprietary bispecific antibody, jointly owned by Genmab and BioNTech, created using Genmab’s DuoBody® technology. It is being co-developed under an agreement in which the companies share all costs and future profits for the product on a 50:50 basis. CD40 and 4-1BB were selected as targets to enhance both dendritic cells (DC) and antigen-dependent ...
Manufactured by:Addex Therapeutics based inGeneva, SWITZERLAND
We are developing muscarinic acetylcholine receptor subtype 4 positive allosteric modulator, or M4 PAM, as a novel orally available treatment for schizophrenia & other psychosis. Schizophrenia affects approximately 24 million people worldwide, requiring lifelong treatment to reduce severe impact on their everyday life. The market for antipsychotics represents over $7B annual sales in the ...
by:Horizon Therapeutics plc based inSaint Kevin`s, IRELAND
A fully human monoclonal antibody against ILT7 that depletes certain dendritic cells. We are investigating daxdilimab in dermatomyositis, discoid lupus erythematosus and lupus nephritis as well conducting Phase 2 clinical trials in alopecia areata and systemic lupus ...
Manufactured by:iMouse GmbH based inBerlin, GERMANY
The iMouse DigiFrame offers a sophisticated solution for researchers looking to digitize rodent home-cage monitoring systems without disrupting existing setups. It is designed to retrofit onto current rack systems, providing continuous 24/7 observation capabilities. This system incorporates high-resolution infrared cameras with a dual-spectrum light system to ensure artifact-free imaging during ...
Manufactured by:ViruSure GmbH based inVienna, AUSTRIA
Recombinant proteins are proteins expressed in cell lines which have been genetically modified by DNA recombinant technology. These therapeutics include recombinant blood clotting factors, hormones, enzymes, interferons, growth factors and other bioengineered ...
Manufactured by:Addex Therapeutics based inGeneva, SWITZERLAND
Our license agreement with Indivior provides for a funded research program, under which we have the right to select drug candidates for exclusive development in certain indications outside of SUD. We plan to develop our selected drug candidates in CMT1a, chronic cough and pain. These indications have been validated with baclofen, an orthosteric agonist of GABAB and present a significant unmet ...
by:Horizon Therapeutics plc based inSaint Kevin`s, IRELAND
Collaboration and option agreement with Q32 Bio to develop ADX-914, a fully human anti-IL-7Rα antibody that re-regulates adaptive immune function by blocking signaling mediated by both IL-7 and TSLP, two key immune ...
Manufactured by:Histocell based inDerio, SPAIN
ASC pre-differentiated to osteoblasts in Histobone scaffold (engineered synthetic bone substitute) for the treatment of bone defects caused by pseudoarthrosis, infections, resections, ...
Manufactured by:Addex Therapeutics based inGeneva, SWITZERLAND
mGlu2 NAM for the treatment of mild neurocognitive disorders, or mNCD. We are developing mGlu2 NAM as a novel orally available treatment for mNCD associated with Alzheimer’s disease, Parkinson’s disease and depressive disorders. The program is in clinical candidate selection phase and we expect to enter IND enabling studies early in H2 ...
Manufactured by:ExeVir Bio BV based inGhent, BELGIUM
XVR011, our lead compound is a potent, broadly neutralising SARS-COV-2 antiviral treatment. XVR011, an enhanced version of VHH72-FC, binds to a highly conserved region on the spikes of SARS-CoV-2, which are essential for the virus to enter the cell. It offers breadth and potency against a range of Sabecoviruses and is not impacted in its binding affinity to, or neutralising capacity of ...